Business Context and Reporting Period
This Form 6-K filing is submitted by Galapagos NV, a foreign private issuer headquartered in Mechelen, Belgium. The report covers the month of April 2018 and was filed on April 16, 2018. The filing primarily serves to incorporate by reference a press release dated April 12, 2018 (Exhibit 99.1). Note: While the request metadata references "Lakefront Biotherapeutics NV," the filing text explicitly identifies the registrant as Galapagos NV.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. This document is a procedural filing to distribute a press release and does not contain a financial statement or earnings report.
Material Changes
No material financial changes versus prior periods are detailed in this text. The filing references a press release regarding a specific event or announcement on April 12, 2018, but the content of that announcement is not included in the provided text, except for a note excluding a quote by Dr. Walid Abi-Saab from incorporation by reference.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, or specific risk factors. It states that the information in the attached press release (Exhibit 99.1) is incorporated by reference into the Company's Registration Statements on Forms F-3 and S-8.
Investor Verification Checklist
- Verify the content of the press release dated April 12, 2018 (Exhibit 99.1), as the core information is not present in this summary text.
- Confirm the identity of the registrant as Galapagos NV, noting the discrepancy with the "Lakefront Biotherapeutics NV" name in the request metadata.
- Review the referenced Registration Statements (Forms F-3 and S-8) for broader context on the company's capital structure and ongoing offerings.
- Check for the specific details regarding Dr. Walid Abi-Saab, as his quote was explicitly excluded from the incorporation by reference in this filing.